{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T01:40:12Z","timestamp":1648690812130},"reference-count":6,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med","J. Jpn. Soc. Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/naika.103.625","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T22:06:46Z","timestamp":1425938806000},"page":"625-629","source":"Crossref","is-referenced-by-count":0,"title":["2. Current Therapy for Chronic Hepatitis C"],"prefix":"10.2169","volume":"103","author":[{"given":"Michio","family":"Imamura","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical & Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical & Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ikeda K, et al: Long-term interferon therapy for 1 year or longer reduces the hepatocellular carciogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastrenterol Hepatol 16: 406-415, 2001.","DOI":"10.1046\/j.1440-1746.2001.02450.x"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Asahina Y, et al: Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52: 518-527, 2010.","DOI":"10.1002\/hep.23691"},{"key":"3","doi-asserted-by":"crossref","unstructured":"7) Tanaka Y, et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109, 2009.","DOI":"10.1038\/ng.449"},{"key":"4","doi-asserted-by":"publisher","unstructured":"8) Chayama K, et al: All-oral combination of daclatasvir plus asunaprevir in interferon-ineligible na\u00efve\/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: results from a phase 3 trial. Hepatology 58: 313A, 2013.","DOI":"10.1002\/hep.26826"},{"key":"5","doi-asserted-by":"crossref","unstructured":"9) Arase Y, et al: Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 79: 1485-1490, 2007.","DOI":"10.1002\/jmv.20925"},{"key":"6","doi-asserted-by":"crossref","unstructured":"10) Izumi N, et al: Inhibition of hepatocellular carcinoma by PegIFN\u03b1-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol 48: 382-390, 2013.","DOI":"10.1007\/s00535-012-0641-9"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":["2\uff0eC\u578b\u6162\u6027\u809d\u708e\u306e\u6700\u65b0\u6cbb\u7642"],"language":"en","deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T20:20:31Z","timestamp":1566418831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/103\/3\/103_625\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.103.625","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}